Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Medical Virology"
DOI: 10.1002/jmv.28210
Abstract: Nucleos(t)ide analogs (NAs) cannot completely suppress the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). This study aimed to identify the risk factors for HCC development in naïve CHB patients treated… read more here.
Keywords: hepatocellular carcinoma; year; nucleos ide; chronic hepatitis ... See more keywords
HBV Antigen‐Guided Switching Strategy From Nucleos(t)ide Analogue to Interferon: Avoid Virologic Breakthrough and Improve Functional Cure
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Medical Virology"
DOI: 10.1002/jmv.70021
Abstract: Little is known for factors associated with virologic breakthrough (VBT) after switching from nucleos(t)ide analogue (NA) to pegylated interferon alpha (Peg‐IFN‐α) for patients with chronic hepatitis B (CHB). Eighty patients who received 48‐week Peg‐IFN‐ɑ and… read more here.
Keywords: hbv; peg ifn; hbcrag log10u; nucleos ide ... See more keywords
Comparison of Interferon-α-based therapy and nucleos(t)ide analogs in preventing adverse outcomes in patients with chronic hepatitis B.
Sign Up to like & getrecommendations! Published in 2021 at "Clinics and research in hepatology and gastroenterology"
DOI: 10.1016/j.clinre.2021.101758
Abstract: BACKGROUND Whether interferon (IFN)-α therapy is better than nucleos(t)ide analogs (NAs) in the prevention of adverse outcomes, including hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB) is still uncertain or controversial. This study… read more here.
Keywords: hcc; nucleos ide; outcomes patients; adverse outcomes ... See more keywords
Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of hepatology"
DOI: 10.1016/j.jhep.2017.09.018
Abstract: BACKGROUND & AIMS It is uncertain if nucleos(t)ide analogue (NA)-induced hepatitis B surface antigen (HBsAg) seroclearance is durable. We investigated the impact of hepatitis B surface antibody (anti-HBs) and duration of consolidation antiviral therapy on… read more here.
Keywords: hepatitis surface; seroclearance; nucleos ide; hbsag seroclearance ... See more keywords
The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analog therapy.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of hepatology"
DOI: 10.1016/j.jhep.2021.04.040
Abstract: Although discontinuation of nucleos(t)ide analogue (NA) treatment before HBsAg loss is part of all current hepatitis B virus (HBV) treatment guidelines for HBeAg-positive patients who achieved HBeAg seroconversion, a treatment endpoint known to be associated… read more here.
Keywords: nucleos ide; hbsag loss; treatment; hbv ... See more keywords
Nucleos(t)ide analogues potentially activate T lymphocytes through inducing interferon expression in hepatic cells and patients with chronic hepatitis B
Sign Up to like & getrecommendations! Published in 2024 at "Scientific Reports"
DOI: 10.1038/s41598-024-76270-8
Abstract: Chronic hepatitis B (CHB) leads to liver inflammation and dysfunction, resulting in liver fibrosis and cancer. Nucleos(t)ide analogues (NAs), inhibitors of hepatitis B virus (HBV), specifically suppress HBV replication. We proposed that immune modulation benefits… read more here.
Keywords: hbv; ide analogues; ast alt; nucleos ide ... See more keywords
Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients
Sign Up to like & getrecommendations! Published in 2022 at "Hepatology Research"
DOI: 10.1111/hepr.13749
Abstract: To summarize HBV‐related biomarkers predicting nucleos(t)ide analogs (NAs) discontinuation and hepatitis B virus (HBV) recurrence after drug withdrawal in chronic hepatitis B (CHB) patients, providing references for clinical medication, so as to manage CHB patients… read more here.
Keywords: biomarkers predicting; nucleos ide; predicting nucleos; hepatitis ... See more keywords
Outcome of nucleos(t)ide analog cessation in patients with treatment for prevention of or against hepatitis B virus reactivation
Sign Up to like & getrecommendations! Published in 2022 at "Hepatology Research"
DOI: 10.1111/hepr.13864
Abstract: We retrospectively investigated patients with administration of nucleos(t)ide analogs (NAs) for prevention of or against hepatitis B virus (HBV) reactivation, and their clinical outcomes after cessation of the NA. read more here.
Keywords: nucleos ide; prevention hepatitis; hepatitis virus;
Negative HBcAg in immunohistochemistry assay of liver biopsy is a predictive factor for the treatment of patients with nucleos(t)ide analogue therapy
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Cellular and Molecular Medicine"
DOI: 10.1111/jcmm.13444
Abstract: The hepatitis B core antigen (HBcAg) is an important target for antiviral response in chronic hepatitis B (CHB) patients. However, the correlation between HBcAg in the hepatocyte nucleus and nucleos(t)ide analogue (NA) therapeutic response is… read more here.
Keywords: week; nucleos ide; ide analogue; hbcag group ... See more keywords
Extrahepatic carcinogenicity of oral nucleos(t)ide analogues in chronic hepatitis B carriers: A 35,000‐Korean outcome study
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Viral Hepatitis"
DOI: 10.1111/jvh.13721
Abstract: Evidence on the carcinogenicity of oral nucleos(t)ide analogues (NAs) is inconclusive and lacks data on the effects by chemical structure of the NAs in patients with chronic hepatitis B (CHB). We aimed to provide definitive… read more here.
Keywords: nucleos ide; carcinogenicity oral; ide analogues; chronic hepatitis ... See more keywords
Validation Study of Scores Predicting Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated With Nucleos(t)ide Analogues
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Viral Hepatitis"
DOI: 10.1111/jvh.70021
Abstract: Chronic hepatitis B virus (HBV) infection is a leading cause of hepatocellular carcinoma (HCC) worldwide. Nucleos(t)ide analogues (NAs) are widely used in chronically HBV‐infected patients, but the risk of HCC still remains in NA‐treated patients.… read more here.
Keywords: risk; score; ide analogues; patients treated ... See more keywords